

Alfons A Den Broeder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6708128/publications.pdf>

Version: 2024-02-01

131
papers

4,951
citations

126907

33
h-index

98798

67
g-index

133
all docs

133
docs citations

133
times ranked

5523
citing authors

#	ARTICLE	IF	CITATIONS
1	The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis. <i>Health Psychology Review</i> , 2023, 17, 148-168.	8.6	7
2	NT-proBNP and sRAGE levels in early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 243-249.	1.1	2
3	Effectiveness and cost-effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis or rheumatoid arthritis and severe limitations: The protocols of two parallel randomized controlled trials. <i>Physiotherapy Research International</i> , 2022, 27, e1933.	1.5	7
4	Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2680-2684.	2.2	4
5	Measurement Properties of the Polymyalgia Rheumatica Activity Score: A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2022, 49, 627-634.	2.0	3
6	Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions. <i>Arthritis Research and Therapy</i> , 2022, 24, 74.	3.5	6
7	Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1392-1399.	0.9	9
8	Prediction Aided Tapering In rheumatoid arthritis patients treated with biologics (PATIO): protocol for a randomized controlled trial. <i>Trials</i> , 2022, 23, .	1.6	2
9	Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells. <i>Rheumatology</i> , 2022, 62, 330-334.	1.9	4
10	Younger age and female gender are determinants of underestimated cardiovascular risk in rheumatoid arthritis patients: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2021, 23, 2.	3.5	8
11	If You Want to Perform a Cost-effectiveness Trial, First Do a Modeling Study. <i>Journal of Rheumatology</i> , 2021, 48, 473-475.	2.0	0
12	AB0873-HPRâ€¦EFFECTIVENESS AND COST-EFFECTIVENESS OF LONGSTANDING EXERCISE THERAPY VERSUS USUAL CARE IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS OR RHEUMATOID ARTHRITIS: THE PROTOCOLS OF TWO PARALLEL RANDOMIZED CONTROLLED TRIALS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1460-1461.	0.9	0
13	OP0017â€¦VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR ANTI-TNF DRUG RESPONSE IN RHEUMATOID ARTHRITIS: A META-ANALYSIS OF THREE LARGE COHORTS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 9.2-10.	0.9	1
14	Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts. <i>Frontiers in Immunology</i> , 2021, 12, 672255.	4.8	6
15	Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 32-37.	0.8	4
16	Seasonal influence on incidence of polymyalgia rheumatica: winter might be coming. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 128, 19-20.	0.8	0
17	Response to: 'Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis' by Wu <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e25-e25.	0.9	1
18	Response to: 'Is it time to redefine the role of low-dose radiotherapy for benign disease?' by Montero <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e35-e35.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Long-term efficacy of low-dose radiation therapy on symptoms in patients with knee and hand osteoarthritis: follow-up results of two parallel randomised, sham-controlled trials. <i>Lancet Rheumatology</i> , The, 2020, 2, e42-e49.	3.9	10
20	NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium. <i>Scientific Reports</i> , 2020, 10, 4316.	3.3	14
21	Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). <i>Trials</i> , 2020, 21, 155.	1.6	6
22	Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial. <i>Trials</i> , 2020, 21, 90.	1.6	14
23	Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis. <i>Arthritis Research and Therapy</i> , 2020, 22, 97.	3.5	22
24	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
25	Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 393.	4.1	29
26	Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00340.	1.3	13
27	Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, annrheumdis-2018-214104.	0.9	43
28	Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium. <i>Scientific Reports</i> , 2019, 9, 14812.	3.3	7
29	Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients. <i>Pharmacogenomics</i> , 2019, 20, 85-93.	1.3	13
30	The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review. <i>Rheumatology</i> , 2019, 58, 1907-1922.	1.9	21
31	Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 439-447.	1.1	7
32	Implementing Psoriatic Arthritis Disease Activity Score“guided treat-to-target in psoriatic arthritis routine clinical practice: (im)possible?. <i>Rheumatology</i> , 2019, 58, 2330-2331.	1.9	7
33	Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. <i>The Cochrane Library</i> , 2019, 2019, CD010455.	2.8	33
34	Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 141-142.	0.9	12
35	The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients. <i>Rheumatology</i> , 2019, 58, 131-134.	1.9	14
36	Exploring longitudinal associations of histologically assessed inflammation with symptoms and radiographic damage in knee osteoarthritis: combined results of three prospective cohort studies. <i>Osteoarthritis and Cartilage</i> , 2019, 27, 71-79.	1.3	22

#	ARTICLE	IF	CITATIONS
37	Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 83-96.	2.0	10
38	Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 414-421.	0.8	0
39	Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 367-372.	0.8	1
40	Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4. <i>Arthritis and Rheumatology</i> , 2018, 70, 1408-1418.	5.6	90
41	Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts. <i>Current Opinion in Rheumatology</i> , 2018, 30, 266-275.	4.3	18
42	P078...A genetic variant of IL-32 is associated with the ex vivo cytokine production of ANTI-TNF treated pbmcs isolated from rheumatoid arthritis patients. , 2018, , .		0
43	Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab. <i>Arthritis and Rheumatology</i> , 2018, 70, 60-68.	5.6	142
44	Comment on 'Ami et al' titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e67-e67.	0.9	1
45	Patient Acceptable Symptom State in Knee Osteoarthritis Patients Succeeds Across Different Patient-reported Outcome Measures Assessing Physical Function, But Fails Across Other Dimensions and Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2018, 45, 122-127.	2.0	10
46	Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients. <i>Scientific Reports</i> , 2018, 8, 14050.	3.3	10
47	The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. <i>Rheumatology</i> , 2018, 57, 1947-1955.	1.9	23
48	THU0215...Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab. , 2018, , .		5
49	Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000654.	3.8	28
50	Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 140-143.	0.8	1
51	bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. <i>Rheumatology and Therapy</i> , 2017, 4, 1-24.	2.3	34
52	What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?. <i>RMD Open</i> , 2017, 3, e000327.	3.8	6
53	Reactive Rather than Proactive Diabetes Management in the Perioperative Period. <i>Hormone and Metabolic Research</i> , 2017, 49, 527-533.	1.5	5
54	Low disease activity (DAS28≤ 3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1693-1699.	0.9	82

#	ARTICLE	IF	CITATIONS
55	Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1716-1722.	0.9	39
56	A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. <i>Rheumatology</i> , 2017, 56, 973-980.	1.9	20
57	Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report. <i>Journal of Rheumatology</i> , 2017, 44, 1536-1543.	2.0	25
58	Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 843-857.	3.3	17
59	Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study. <i>Journal of Rheumatology</i> , 2017, 44, 1325-1330.	2.0	21
60	Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial. <i>BMC Dermatology</i> , 2017, 17, 6.	2.1	15
61	Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis and Rheumatology</i> , 2017, 69, 301-308.	5.6	56
62	FRI0223â€¦Anti-ccp is an independent predictor of 12-month eular response in patients with ra treated with abatacept. , 2017, , .		0
63	SAT0132â€¦The rheumatoid arthritis flare questionnaire (RA-FQ): results of rasch analysis and feedback on real-world applications from international RA patients and clinicians. , 2017, , .		0
64	THU0695â€¦The RA FLARE questionnaire (RA-FQ) is responsive to change in ra symptoms and impacts in clinical and observational trials. , 2017, , .		0
65	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 403.	1.6	18
66	Reply. <i>Arthritis Care and Research</i> , 2016, 68, 1051-1051.	3.4	0
67	THU0058â€¦Prediction of Successful Dose Reduction or Discontinuation of Biologics in Patients with Rheumatoid Arthritis: A Systematic Review. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 198.3-199.	0.9	1
68	FRI0586â€¦The Effects of An Educational Meeting and Subsequent Computer Reminders on The Ordering of Laboratory Tests by Rheumatologists: An Interrupted Time Series Analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 654.1-654.	0.9	0
69	AB0342â€¦Study on Abatacept and Tocilizumab Attenuation (SONATA) in Rheumatoid Arthritis Patients: A Retrospective, Explorative Cohort Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1019.1-1019.	0.9	1
70	THU0142â€¦High Similarity between ex-vivo Inhibited Cytokine Profiling by Golimumab and Adalimumab as A Putative Explanation for Inferior Treatment Response To Golimumab after Adalimumab Failure in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 232.3-233.	0.9	0
71	The value of routine creatine kinase and thyroid stimulating hormone testing in patients with suspected fibromyalgia: a cross-sectional study. <i>Rheumatology</i> , 2016, 55, 1273-1276.	1.9	0
72	Choosing Wisely in Daily Practice: An Intervention Study on Antinuclear Antibody Testing by Rheumatologists. <i>Arthritis Care and Research</i> , 2016, 68, 562-569.	3.4	14

#	ARTICLE	IF	CITATIONS
73	Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1939-1944.	0.9	46
74	Preface. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 525-526.	3.3	0
75	AB0247â€¦Associations of a Multi-Biomarker Disease Activity Score with Clinical and Radiographic Parameters in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 974.1-974.	0.9	1
76	AB0246â€¦Predictive Value of a Multi-Biomarker Disease Activity Score for Successful Dose Reduction of TNF Inhibitors in Rheumatoid Arthritis: Results of the Dress Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 973.3-974.	0.9	2
77	How to define worsening in osteoarthritis? Development and validation of preliminary criteria for clinically important worsening in knee and hip osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2015, 23, A348.	1.3	0
78	SAT0025â€¦Shift in Genetic Composition of an IL-32 Promoter Polymorphism Results in a Higher Cytokine Production in RA Patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 657.3-658.	0.9	3
79	Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 543-549.	3.3	18
80	Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2260-2261.	0.9	15
81	Controlling the Cost Spent on Expensive Biologic Agents: an Example of Net Monetary Savings By Dose Optimisation of Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis Patients. <i>Value in Health</i> , 2015, 18, A647-A648.	0.3	0
82	Personalizing Treatment Targets in Rheumatoid Arthritis by Using a Simple Prediction Model. <i>Journal of Rheumatology</i> , 2015, 42, 398-404.	2.0	11
83	Ultrasonographic predictors for clinical and radiological progression in knee osteoarthritis after 2 years of follow-up. <i>Rheumatology</i> , 2015, 54, 2000-2003.	1.9	23
84	Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. <i>BMJ</i> , The, 2015, 350, h1389-h1389.	6.0	135
85	The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 998-1003.	0.9	121
86	De-intensifying treatment in established rheumatoid arthritis (RA): Why, how, when and in whom can DMARDs be tapered?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 550-565.	3.3	45
87	THU0208â€¦Criteria for Clinical Important Worsening in Knee and Hip Osteoarthritis: A First Development and Validation Round. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 253.3-254.	0.9	0
88	Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis. <i>Patient Preference and Adherence</i> , 2014, 8, 1635.	1.8	46
89	THU0228â€¦Validity of Omeract Preliminary Flare Questions in a Randomized Controlled Trial, that Assesses Impact of Disease Activity Guided Down-Titration of Anti-TNF Treatment in Rheumatoid Arthritis Patients in Low Disease Activity. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 260.3-261.	0.9	2
90	Measuring Flares in Rheumatoid Arthritis. (Why) Do We Need Validated Criteria?. <i>Journal of Rheumatology</i> , 2014, 41, 189-191.	2.0	9

#	ARTICLE	IF	CITATIONS
91	Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: A randomized controlled trial. <i>Patient Education and Counseling</i> , 2014, 94, 356-361.	2.2	55
92	Acute and probable chronic Q fever during anti-TNF \pm and anti B-cell immunotherapy: a case report. <i>BMC Infectious Diseases</i> , 2014, 14, 330.	2.9	5
93	Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida et al. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e4-e4.	0.9	2
94	OPO140-HPR \hat{e} ...Preliminary Results of A Randomized Clinical TRIAL Comparing the Effectiveness of A Non-Pharmacological Multidisciplinary Group-Based Treatment Program with A Telephone Monitored Program on Daily Function in Patients with Generalized Osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 113.2-113.	0.9	0
95	OPO005-HPR \hat{e} ...Perceived Need to Take Medication is Associated with Medication Non-Adherence in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 61.2-61.	0.9	0
96	Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. <i>The Cochrane Library</i> , 2014, , CD010455.	2.8	61
97	Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 350.	1.9	53
98	Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 895-900.	0.9	124
99	Longitudinal impact of joint pain comorbidity on quality of life and activity levels in knee osteoarthritis: data from the Osteoarthritis Initiative. <i>Rheumatology</i> , 2013, 52, 543-546.	1.9	60
100	Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1800-1805.	0.9	106
101	Improvement in deployment of MRI of the sacroiliac joints in patients suspected for spondyloarthritis using a targeted intervention: a case study. <i>Rheumatology</i> , 2013, 52, 933-938.	1.9	5
102	Antidrug antibodies to tumour necrosis factor specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective; comment on the article by Vincent <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e14-e14.	0.9	4
103	Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. <i>Rheumatology</i> , 2013, 52, 1500-1508.	1.9	47
104	The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non \hat{e})response to infliximab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 939-945.	2.4	32
105	Should We Redefine Treatment Targets in Rheumatoid Arthritis? Low Disease Activity Is Sufficiently Strict for Patients Who Are Anticitrullinated Protein Antibody-negative. <i>Journal of Rheumatology</i> , 2013, 40, 1268-1274.	2.0	26
106	AB0324 \hat{e} ...Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity: a pilot study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A886.2-A886.	0.9	0
107	Dose REDuction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 299.	1.9	39
108	OP0116 \hat{e} ...Cost-effectiveness and cost-utility analysis of treat-to-target versus usual care in early rheumatoid arthritis: Results of the dream registry. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 92.2-92.	0.9	0

#	ARTICLE	IF	CITATIONS
109	Feasibility and potential effectiveness of a non-pharmacological multidisciplinary care programme for persons with generalised osteoarthritis: a randomised, multiple-baseline single-case study. <i>BMJ Open</i> , 2012, 2, e001161.	1.9	15
110	A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 845-850.	0.9	141
111	Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1849-1854.	0.9	88
112	The Dutch Lower Extremity Functional Scale was highly reliable, valid and responsive in individuals with hip/knee osteoarthritis: a validation study. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 117.	1.9	75
113	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 184.	1.9	25
114	Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis. <i>Patient Education and Counseling</i> , 2012, 89, 143-151.	2.2	17
115	Validation Study of Existing Gene Expression Signatures for Anti-TNF Treatment in Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2012, 7, e33199.	2.5	61
116	Joint pain comorbidity, health status, and medication use in hip and knee osteoarthritis: A cross-sectional study. <i>Arthritis Care and Research</i> , 2012, 64, 54-58.	3.4	47
117	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 12.	1.9	35
118	Fatigue in knee and hip osteoarthritis: the role of pain and physical function. <i>Rheumatology</i> , 2011, 50, 1894-1900.	1.9	41
119	Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 877-878.	0.9	32
120	Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. <i>Rheumatology</i> , 2011, 50, 196-203.	1.9	103
121	Age-Related Health Hazards in Old Patients with First-Time Referral to a Rheumatologist: A Descriptive Study. <i>Arthritis</i> , 2011, 2011, 1-7.	2.0	2
122	The effects of doxycycline on reducing symptoms in knee osteoarthritis: results from a triple-blinded randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1191-1196.	0.9	32
123	Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. <i>Rheumatology</i> , 2011, 50, 1320-1330.	1.9	37
124	Effectiveness of a Third Tumor Necrosis Factor- β -blocking Agent Compared with Rituximab After Failure of 2 TNF-blocking Agents in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 2355-2361.	2.0	23
125	557 EVIDENCE-BASED TAILORED CONSERVATIVE TREATMENT OF KNEE AND HIP OA: BETWEEN KNOWING AND DOING. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S249-S250.	1.3	0
126	Non-pharmacological care for patients with generalized osteoarthritis: design of a randomized clinical trial. <i>BMC Musculoskeletal Disorders</i> , 2010, 11, 142.	1.9	20

#	ARTICLE	IF	CITATIONS
127	Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. <i>Rheumatology</i> , 2010, 49, 1801-1803.	1.9	44
128	Time to achieve remission determines time to be in remission. <i>Arthritis Research and Therapy</i> , 2010, 12, R97.	3.5	52
129	Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?. <i>Rheumatology</i> , 2009, 48, 1247-1253.	1.9	7
130	The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 2171-2177.	2.0	48
131	Nephrotic syndrome associated with anti-tumor necrosis factor ? therapy in a patient with rheumatoid arthritis: Comment on the article by Charles et al. <i>Arthritis and Rheumatism</i> , 2002, 46, 1691-1693.	6.7	6